Recent Updates — VTAK
Effective October 5, 2026, Flyte Aviation, Inc. (formerly Catheter Precision, Inc.) completed a 1-for-10 reverse stock split of its common stock, reducing the issued and outstanding shares to approximately 2,101,987. The company simultaneously changed its corporate name and NYSE American ticker symbol from VTAK to VJET. This rebranding marks a strategic pivot toward becoming an AI-driven technology platform for private jet charter services, aiming to disrupt the $11.6 billion U.S. market. The company intends to invest in digital marketing and platform upgrades during Q4 2026 while maintaining its life sciences operations. Flyte Aviation operates as a technology-enabled provider of private aviation services.
Catheter Precision, Inc. reported that its 1-for-10 reverse stock split becomes effective on October 5, 2026, at which point the company will be renamed Flyte Aviation, Inc., and trading will resume under the symbol VJET. The filing also details results from the September 30, 2026 annual meeting, where shareholders approved a reincorporation from Delaware to Nevada, an amendment to increase equity plan reserves by 5,000,000 shares, and a one-time repricing of underwater stock options to $0.152 per share (post-split: $1.52). The company operates in the medical device industry, specifically focusing on catheter technologies.
On September 24, 2026, Catheter Precision, Inc. announced that its Board approved an amendment to the Certificate of Incorporation to change the company's name to Flyte Aviation, Inc., and to effect a 1-for-10 reverse stock split of its common stock. The reverse split was previously approved by stockholders at a special meeting on April 15, 2026. These changes are expected to become effective at 12:01 a.m. Eastern Time on October 5, 2026. At the Effective Time, every ten shares of common stock will be combined into one share, with no fractional shares issued; holders of fractional shares will receive cash in lieu thereof. The company intends to file a certificate of amendment with the Delaware Secretary of State to finalize these changes. The common stock is expected to begin trading on a split-adjusted basis under the new name and ticker symbol VJET on October 5, 2026. Catheter Precision, Inc. operates in the medical device industry, specifically focusing on catheter technologies.
On July 30, 2026, Catheter Precision, Inc. closed the sale of 2,821 shares of Series C-4 Convertible Preferred Stock for aggregate gross proceeds of $2,821,000. The issuance was executed under an Additional Investment Right within a Securities Purchase Agreement dated March 9, 2026, with Dawson James Securities acting as placement agent. Proceeds are designated for working capital, general corporate purposes, and the redemption of outstanding Series B Convertible Preferred Stock. This transaction involves unregistered equity securities exempt from registration under Regulation D and results in dilution to existing common shareholders. Catheter Precision, Inc. operates in the medical device industry, specializing in catheter technologies.
Catheter Precision, Inc. filed an amendment to its March 9, 2026 Form 8-K/A to include audited financial statements and pro forma information for its acquisition of Fly Flyte, Inc. and Ponderosa Air, LLC. The transaction was completed on March 9, 2026, with Catheter Precision acquiring 100% ownership through a combination of cash, promissory notes, and Series D Preferred Stock issuance. The aggregate purchase price was $11,554,827, comprising approximately $5.8 million in cash (including a $5 million note) and $5.8 million in equity. Pro forma results for the year ended December 31, 2025, show combined revenues of $1.8 million and a net loss of $23.3 million, reflecting transaction costs and purchase accounting adjustments including $10.1 million in goodwill. Catheter Precision operates in the medical device industry.
Catheter Precision, Inc. closed the sale and issuance of 3,470 shares of Series C-3 Convertible Preferred Stock for aggregate gross proceeds of $3,470,000. The preferred stock is convertible into common stock at an initial conversion price of $0.632 per share, subject to a floor price of $0.35 per share. The company intends to use the net proceeds for working capital, loan repayment, and general corporate purposes. Catheter Precision, Inc. operates in the medical device industry and develops precision catheter technology.